Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017.

Huixian Li, Wanhong Lu, Ani Wang, Hongli Jiang, Jun Lyu
Author Information
  1. Huixian Li: Department of Nephrology, Kidney Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. ORCID
  2. Wanhong Lu: Department of Nephrology, Kidney Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  3. Ani Wang: Department of Nephrology, Kidney Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  4. Hongli Jiang: Department of Blood Purification, Kidney Hospital, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  5. Jun Lyu: Department of Nephrology, Kidney Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Abstract

AIMS/INTRODUCTION: Type 2 diabetes mellitus has been a leading cause of Disease">chronic kidney Disease (CKD), with a heterogeneous distribution worldwide. Optimal healthcare planning requires an understanding of how the burden of CKD as a result of type 2 diabetes mellitus has changed over time and geographic location, as well as the potential roles of sociodemographic, clinical and behavioral factors in these changes.
MATERIALS AND METHODS: We used the Global Burden of Disease data from 1990 to 2017 at the global, regional and national levels to investigate changes in the incidence, Disease">death and disability-adjusted life years of CKD as a result of type 2 diabetes mellitus, incorporating both epidemiological research and risk factor monitoring.
RESULTS: The incident cases of CKD as a result of type 2 diabetes mellitus worldwide in 2017 had increased by 74% compared with 1990; total disability-adjusted life years had increased by 113%, mainly attributable to population expansion and demographic transition. The Sociodemographic Index was significantly and negatively correlated with overall CKD as a result of type 2 diabetes mellitus burden. However, in 82 countries and territories, the burden was not alleviated in parallel with socioeconomic development.
CONCLUSIONS: CKD as a result of type 2 diabetes mellitus has been the main contributor to the increasing burden of CKD over the past several decades. We suggest a more pragmatic approach focusing on early diagnosis, primary care and adequate follow up to reduce mortality and the long-term burden in low-to-middle Sociodemographic Index regions. Interventions should address high systolic blood pressure, as well as overweight and obesity problems, especially in high-income regions.

Keywords

References

  1. Lancet. 2018 Nov 10;392(10159):1736-1788 [PMID: 30496103]
  2. Kidney Int Suppl (2011). 2018 Feb;8(2):52-63 [PMID: 30675439]
  3. JAMA Intern Med. 2018 Feb 1;178(2):188-195 [PMID: 29255898]
  4. Clin J Am Soc Nephrol. 2019 Apr 5;14(4):515-522 [PMID: 30846462]
  5. JAMA. 2011 Jun 22;305(24):2532-9 [PMID: 21693741]
  6. J Diabetes Investig. 2021 Mar;12(3):346-356 [PMID: 32654341]
  7. Cochrane Database Syst Rev. 2017 Jun 08;6:CD010137 [PMID: 28594069]
  8. Kidney Int. 2019 Mar;95(3):501-505 [PMID: 30784660]
  9. PLoS One. 2019 Feb 4;14(2):e0210213 [PMID: 30716100]
  10. JAMA. 2016 Aug 9;316(6):602-10 [PMID: 27532915]
  11. Lancet. 2018 Nov 10;392(10159):1995-2051 [PMID: 30496106]
  12. Transplantation. 2015 Mar;99(3):476-81 [PMID: 25680089]
  13. Nephrol Dial Transplant. 2012 Sep;27(9):3435-42 [PMID: 22942175]
  14. Kidney Int Suppl (2011). 2018 Feb;8(2):64-73 [PMID: 30675440]
  15. J Diabetes Complications. 2019 Jan;33(1):39-45 [PMID: 30482493]
  16. N Engl J Med. 2017 Jul 6;377(1):13-27 [PMID: 28604169]
  17. Popul Health Metr. 2010 Oct 22;8:29 [PMID: 20969750]
  18. N Engl J Med. 2017 Apr 13;376(15):1419-1429 [PMID: 28402773]
  19. Kidney Int Suppl (2011). 2017 Oct;7(2):145-153 [PMID: 30675429]
  20. J Am Soc Nephrol. 2013 Feb;24(2):302-8 [PMID: 23362314]
  21. Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045 [PMID: 28522654]
  22. Lancet. 2017 Jul 15;390(10091):231-266 [PMID: 28528753]
  23. Kidney Int. 2003 Jan;63(1):225-32 [PMID: 12472787]
  24. Lancet. 2018 Nov 10;392(10159):1789-1858 [PMID: 30496104]
  25. Kidney Int. 2019 Feb;95(2):242-248 [PMID: 30665560]
  26. JAMA. 2014 May 7;311(17):1778-86 [PMID: 24794371]
  27. Lancet. 2016 Apr 9;387(10027):1513-1530 [PMID: 27061677]
  28. Lancet. 2020 Feb 29;395(10225):709-733 [PMID: 32061315]
  29. Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii121-ii128 [PMID: 28201666]
  30. Curr Diab Rep. 2019 Mar 2;19(4):18 [PMID: 30826889]
  31. Int J Hyg Environ Health. 2018 May;221(4):602-608 [PMID: 29706436]
  32. Kidney Int. 2018 Sep;94(3):567-581 [PMID: 30078514]
  33. Diabetes Care. 2014 Jun;37(6):1660-7 [PMID: 24623028]
  34. N Engl J Med. 2016 Sep 1;375(9):905-6 [PMID: 27579659]
  35. Nat Rev Nephrol. 2019 Apr;15(4):193-194 [PMID: 30723305]
  36. Lancet. 2018 Nov 10;392(10159):1859-1922 [PMID: 30415748]
  37. Lancet. 2018 Nov 10;392(10159):1923-1994 [PMID: 30496105]
  38. Kidney Int Suppl (2011). 2012 Aug;2(3):275-278 [PMID: 25018942]
  39. Nephrol Dial Transplant. 2013 Oct;28(10):2553-69 [PMID: 23737482]
  40. Eur J Epidemiol. 2012 Jan;27(1):39-46 [PMID: 22160277]

MeSH Term

Diabetes Mellitus, Type 2
Female
Global Burden of Disease
Humans
Male
Renal Insufficiency, Chronic
Risk Factors

Word Cloud

Created with Highcharts 10.0.0diabetesmellitusCKDresulttype 2burdenkidneydiseaseGlobalBurdenDisease19902017Type 2chronicworldwidewellchangesdisability-adjustedlifeyearsincreasedSociodemographicIndexregionsAIMS/INTRODUCTION:leadingcauseheterogeneousdistributionOptimalhealthcareplanningrequiresunderstandingchangedtimegeographiclocationpotentialrolessociodemographicclinicalbehavioralfactorsMATERIALSANDMETHODS:useddataglobalregionalnationallevelsinvestigateincidencedeathincorporatingepidemiologicalresearchriskfactormonitoringRESULTS:incidentcases74%comparedtotal113%mainlyattributablepopulationexpansiondemographictransitionsignificantlynegativelycorrelatedoverallHowever82countriesterritoriesalleviatedparallelsocioeconomicdevelopmentCONCLUSIONS:maincontributorincreasingpastseveraldecadessuggestpragmaticapproachfocusingearlydiagnosisprimarycareadequatefollowreducemortalitylong-termlow-to-middleInterventionsaddresshighsystolicbloodpressureoverweightobesityproblemsespeciallyhigh-incomeChangingepidemiology2017:EstimatesChronic

Similar Articles

Cited By (51)

Current status of diabetic kidney disease and latest trends in management.Highly Sensitive Magnetoelastic Biosensor for Alpha2-Macroglobulin Detection Based on MnFeO@chitosan/MWCNTs/PDMS Composite.Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.Global, regional and national burden of tracheal, bronchus, and lung cancer attributable to ambient particulate matter pollution from 1990 to 2021: an analysis of the global burden of disease study.Epidemiological status, development trends, and risk factors of disability-adjusted life years due to diabetic kidney disease: A systematic analysis of Global Burden of Disease Study 2021.Global, Regional, and National Burden of CKD due to Glomerulonephritis from 1990 to 2019: A Systematic Analysis from the Global Burden of Disease Study 2019.The prevalence of chronic kidney disease among type 2 diabetes mellitus patients in central South Africa.Combination of canagliflozin and puerarin alleviates the lipotoxicity to diabetic kidney in mice.Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: A Meta-analysis.
See all "Cited by" articles